Organogenesis Holdings (STU:2PQ) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


STU:2PQ Organogenesis Holdings Inc STU:2PQ
67 GF Score
Price €2.12
GF Value €2.76
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Organogenesis Holdings Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Organogenesis Holdings's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

STU:2PQ vs SIGA, ELTP, TKNO: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Organogenesis Holdings Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's Margin of Safety % (DCF Earnings Based) falls into.


STU:2PQ
67GF Score
Organogenesis Holdings Inc STU:2PQ
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Organogenesis Holdings (STU:2PQ) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of €2.12 is trading 23.2% below its estimated GF Value™ of €2.76. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for STU:2PQ:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €2.76 vs. price of €2.12 (23.2% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the STU:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organogenesis Holdings Business Description

Other Exchanges ORGO:USA2PQ:Germany
Address 85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score

Get the complete analysis for STU:2PQ

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.12
Price
€2.76
GF Value